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Abstract
AIM: To assess the efficacy and safety of anti-
thrombotic drugs (antiplatelet or anticoagulant drugs) 
compared to no antithrombotic treatment or placebo in 
patients with heart failure (HF) and sinus rhythm. 
METHODS: We searched Medline and Cochrane 
Library for randomized controlled trials evaluating 
antithrombotic treatment and no antithrombotic 
treatment in patients with HF and sinus rhythm. Risk 
ratio (RR) and 95%CIs were estimated performing 
meta-analysis with random effects method. 
RESULTS: Two studies met the inclusion criteria: Heart 
failure Long-term Antithrombotic Study and Warfarin/
Aspirin Study in Heart failure, with 336 patients and 
mean follow-up 1.8-2.25 years. Stroke risk was not 
reduced by acetylsalicylic acid (RR = 1.18, 95%CI: 
0.17-8.15), oral anticoagulation (RR = 0.30, 95%CI: 
0.03-2.65) or overall antithrombotic drugs (RR = 
0.52, 95%CI: 0.10-2.74). Acetylsalicylic acid showed a 
significant increased risk of worsening HF (RR = 1.78, 
95%CI: 1.08-2.92), while oral anticoagulation had no 
impact in this outcome (RR = 1.03, 95%CI: 0.61-1.75). 
Overall antithrombotic drugs showed a significant 
risk increase of major bleeding (RR = 6.99, 95%CI: 
0.89-54.64). 
CONCLUSION: Best available evidence does not support 
the routine use of antithrombotic drugs in patients with 
HF and sinus rhythm. These drugs, particularly oral anti-
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coagulation has the hazard of increase significantly major 
bleeding risk.
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Core tip: In patients with atrial fibrillation, chronic 
heart failure (CHF) increases thromboembolic risk and 
oral anticoagulation is essential to decrease the risk of 
thromboembolic complications. Evidence suggests a 
positive association between CHF, impaired hemostasis 
and thromboembolic events. Whether antithrombotic 
drugs should be recommended for these patients (in 
sinus rhythm) is still debated. We looked for the best 
available evidence and we found 2 studies fulfilling the 
inclusion criteria. We performed a meta-analysis of 
antithrombotic drugs vs  placebo and strengthened that 
antithrombotic drugs do not decrease the risk of stroke 
(fatal or non-fatal) and increase the risk of major 
bleeding.
Caldeira D, Cruz I, Calé R, Martins C, Pereira H, Ferreira JJ, 
Pinto FJ, Costa J. Antithrombotic treatment in chronic heart 
failure and sinus rhythm: Systematic review. World J Meta-
Anal 2015; 3(1): 36-42  Available from: URL: http://www.
wjgnet.com/2308-3840/full/v3/i1/36.htm  DOI: http://dx.doi.
org/10.13105/wjma.v3.i1.36
INTRODUCTION
Chronic heart failure (CHF) is an increasingly prevalent 
cardiovascular disease with significant associated 
morbidity and mortality[1]. CHF constitutes a significant 
economic burden[2,3], which is expected to increase 
over the next decades due to increasing prevalence of  
associated diseases and risk factors as well as population 
aging. Former observational studies suggest a positive 
association between CHF, impaired hemostasis and 
thromboembolic events[4,5]. In patients with atrial 
fibrillation (AF), CHF increases thromboembolic risk 
and oral anticoagulation is the cornerstone of  AF 
treatment aiming to decrease the risk of  thromboembolic 
complications[6]. The results from the WARCEF trial 
(Warfarin vs Aspirin in Reduced Cardiac Ejection 
Fraction) has highlighted the role of  antithrombotic 
treatment in patients with CHF and sinus rhythm[7]. There 
were no differences between warfarin and acetylsalicylic 
acid in the primary outcome (time to the first event in 
a composite end point of  ischemic stroke, intracerebral 
hemorrhage, or death from any cause). However, warfarin 
was associated with fewer stroke events (2.5% vs 4.7%) 
but also with a higher rate of  major bleeding events (5.8% 
vs 2.7%). The clinical interpretation of  these findings was 
that the choice between warfarin and aspirin should be 
made on the basis of  the individual patient[8].
Previous systematic reviews with meta-analyses com-
paring oral anticoagulation (namely warfarin) and ace-
tylsalicylic acid in patients with CHF and sinus rhythm 
reached conclusions overlapping those from the WARCEF 
study[9-13].
Although much effort have been done comparing and 
discussing the relative effectiveness of  oral anticoagulation 
vs acetylsalicylic acid in patients with CHF and sinus 
rhythm, significantly less is known about the true efficacy 
of  the overall antithrombotic treatment. Therefore, we 
aimed to perform a systematic review to better estimate 
the true clinical benefit of  antithrombotic treatments 
(oral anticoagulation or antiplatelet drugs) against placebo, 
standard care or no treatment, in patients with CHF and 
sinus rhythm.
MATERIALS AND METHODS
Guidance
This work followed PRISMA guidelines for systematic 
reviews and meta-analyses promoted by the EQUATOR 
network[14].
Eligibility criteria
We have searched for all randomized controlled trials 
(RCTs) evaluating patients with CHF and sinus rhythm 
treated with oral antithrombotic therapy or control. 
We considered for antithrombotic treatments both oral 
anticoagulants (such as vitamin K antagonists, like warfarin, 
acenocoumarol or phenprocoumon) and antiplatelet 
drugs [such as acetylsalicylic acid (ASA), clopidogrel or 
ticlopidine]. We allowed controls under placebo, standard 
care or no antithrombotic treatment. Studies had to report 
clinical and/or echocardiographic features for the enrolled 
CHF patients, such as impaired left ventricle ejection 
fraction or shortening fraction.
Database and search method
Medline and Cochrane Library (CENTRAL) databases 
were searched from inception to November 2013 for 
eligible studies. The search strategy details are available 
at the Online Supplementary Material. We considered all 
studies irrespective of  language. References of  obtained 
studies were also comprehensively searched and cross-
checked to identify possible missing studies.
Studies and data selection
Citations obtained from electronic search were inde-
pendently screened by two authors, followed by full-text 
assessment of  potentially eligible studies for inclusion in 
accordance with previously mentioned criteria.
Primary outcome was stroke (fatal or non-fatal). 
Secondary outcomes were all-cause mortality, myocardial 
infarction, worsening heart failure (HF), major bleeding 
and a composite of  major adverse clinical events, defined 
as the combination of  mortality, stroke, myocardial 
infarction and HF.
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We extracted detailed data about demographics, 
comorbidities, interventions, follow-up and outcomes. 
Data extraction and data entry into software was double-
checked. Disagreements were resolved by consensus.
Quality reporting assessment
Quality of  reporting was analysed by using a qualitative 
classification according to risk of  bias (high, unclear or 
low risk), adapted from Cochrane Collaboration’s Tool[15]. 
Studies were not excluded based on quality of  reporting.
Statistical analysis 
Outcomes data were summarized as frequencies. Statistical 
analyses were performed using the RevMan version 
5.2.6 (The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2012) to derive forest plots with pooled 
estimates of  risk ratios (RR) and their 95%CI. Statistical 
heterogeneity was assessed with χ 2 test and quantified 
with Higgins I2 test[16]. Pooled results estimates were based 
on the random or fixed effects model according to the 
existence (I2 ≥ 50%) or not (I2 < 50%) of  significant 
heterogeneity[17]. Publication bias was assessed through 
visual inspection of  funnel plots symmetry and Peters’ 
regression tests[18,19]. Pooled results were evaluated for the 
overall antithrombotic treatment, as well separately for 
antiplatelet and anticoagulation groups.
RESULTS
Search
After title and abstract screening of  citations obtained 
in Medline and Cochrane Library, 196 citations were 
retrieved. One-hundred and eighty seven studies did not 
meet inclusion criteria through initial assessment: 107 
included AF patients; 56 studies were not randomized 
and 24 did not address the pretended topic (either 
different population and/or other interventions).
The remaining 9 studies were fully-evaluated, of  
which 7 were further excluded: 5 were observational 
studies, and 2 RCTs did not include a placebo, standard 
care or no antithrombotic treatment arm (WARCEF and 
WATCH trials)[5,20]. Therefore, 2 RCTs were eligible for 
the purpose of  this systematic review[21,22]. The search 
of  reference lists of  review articles and included studies 
failed to identify any additional eligible study[23-27]. Figure 
1 shows the flowchart of  studies’ selection.
Characteristics of obtained studies and quality of 
reporting
Studies Warfarin/Aspirin Study in Heart failure (WASH) 
and Heart failure Long-term Antithrombotic Study 
(HELAS) met the outlined inclusion criteria[21,22].
WASH study was an open-label RCT with blinded 
endpoint assessment, published in 2004. WASH enrolled 
254 patients (80 warfarin; 80 ASA; 94 no anti-thrombotic 
treatment) with CHF and sinus rhythm and followed 
them for a mean period of  2.25 years. About 60% had 
CHF of  ischemic etiology, 75% of  the patients were 
male, mean age was 63 years old, and 30% were in New 
York Heart Association class Ⅲ/Ⅵ. About 34% of  the 
patients had hypertension, and 20% had diabetes. In 
terms of  echocardiography mean parameters, patients 
had a fractional shortening of  15% and a left-ventricular 
end-diastolic diameter of  66 mm. Regarding treatments, 
the daily dosage of  acetylsalicylic acid was 300 mg and 
international normalized ratio (INR) target for warfarin-
treated patients was 2.5 (range 2-3). Primary outcome was 
the composite of  all-cause death, non-fatal myocardial 
infarction, or non-fatal stroke[21].
HELAS study was published in 2006 and included 
two comparisons: warfarin vs acetylsalicylic acid in 
patients with CHF of  ischemic etiology (not evaluated 
in this review due to absence of  a placebo/no treatment 
control arm); and warfarin vs placebo in 82 patients (38 
vs 44) with dilated non-ischemic CHF in sinus rhythm. 
Study’s mean follow was 1.8 years. Most of  the patients 
were male and mean age was 55 years. Hypertension was 
present in 25% of  the patients, and diabetes in 11%. No 
significant differences were noticed in the main baseline 
characteristics. Echocardiographic features of  these 
patients were remarkable for a baseline ejection fraction 
of  28%, left ventricle end-systolic diameter of  58 mm 
and end-diastolic diameter of  70 mm. Target INR for 
warfarin treatment was 2-3. Primary outcome was the 
composite of  all-cause mortality, non-fatal stroke, non-
fatal myocardial infarction, peripheral or pulmonary 
embolism, hospitalisation, or HF worsening[22].
Quality of  reporting assessment is available in Figure 
2. The main methodological flaws were the open-label 
design of  WASH and the unknown method of  allocation 
concealment in HELAS.
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187 references excluded after abstract screening:
   Patients w/AF (107)
   Not RCT (56)
   Other subject (24)
Excluded studies:
   Observational studies (5)
   Without a eligible control arm (2)
WASH
   Warfarin arm
   Acetylsalicylic acid arm
   No antithrombotic drugs arm
HELAS (only non-ischemic population)
   Warfarin arm
   Placebo arm
196 references retrieved from search strategy
9 studies
Included for analysis:
2 RCTs (WASH and HELAS)
Figure 1  Flowchart of studies’ selection. AF: Atrial fibrillation; RCT: Randomized 
controlled trial; WASH: Warfarin/Aspirin Study in Heart failure; HELAS: Heart failure 
Long-term Antithrombotic Study.
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myocardial infarction risk in patients with systolic HF and 
sinus rhythm.
Antiplatelet drug/acetylsalicylic acid, but not warfarin, 
showed increased risk of  the composite outcome of  
mortality, stroke, myocardial infarction, and worsening 
HF, most probably due to the increased risk of  CHF 
worsening. Statistical heterogeneity was present in the 
evaluation of  mortality when comparing antithrombotic 
drugs with control (I2 = 58%). Figure 3 shows the pooled 
results. Publication bias was not evaluated due to the 
scarcity of  studies[28].
DISCUSSION
Our main findings were the lack of  proven efficacy 
of  antithrombotic treatments, in patients with systolic 
HF and sinus rhythm, in the risk reduction of  clinically 
important outcomes such as stroke, mortality and 
myocardial infarction; moreover, warfarin is associated to 
a significant 9-fold increased risk of  major bleeding; and 
acetylsalicylic acid was associated with increased risk of  
CHF worsening. 
The spotlight of  this theme looks for Warfarin vs 
Acetylsalicylic acid comparison. By conducting this 
systematic review, the authors aimed to move back to 
the original problem and ask the question of  whether 
antithrombotic treatments are, in the first place, effective 
in the treatment of  CHF with sinus rhythm. If  we accept 
that RCTs are the unique type of  clinical studies that can 
prove causality with a reasonable margin of  error, our 
results show that these interventions still have to prove 
their efficacy in this population, knowing that they owe 
an important bleeding risk. Furthermore, our attempt to 
perform a bayesian mixed treatment comparison meta-
analysis, with data from clopidogrel arm from WATCH 
study[20], and warfarin vs acetylsalicylic acid presented 
in multiple systematic reviews and meta-analyses, failed 
due to high inconsistency in the statistical analysis of  the 
network (data not shown). Although this inconsistence 
strongly compromises the results of  such exercise, it is 
worth to report that placebo had a high probability of  
being the best treatment option. This reinforces the need 
of  further trials to elucidate whether these interventions 
do/do not interfere with the prognosis, rather than have 
contradictory signs.
Accordingly, the 2012 consensus document of  the HF 
Association of  the European Society of  Cardiology (ESC) 
and the ESC Working Group on Thrombosis corroborates 
our conclusions[29]. This consensus document stated that 
warfarin and acetylsalicylic acid should not be routinely 
used for thromboprophylaxis in patients with systolic 
HF and sinus rhythm, in the absence of  concomitant 
comorbidities with clear indications for anticoagulation 
(e.g., AF) or acetylsalicylic acid (e.g., documented coronary 
artery disease).
Safety concerns regarding acetylsalicylic acid and 
HF (in patients with previously optimized background 
therapy with drugs such as angiotensin-converting enzyme 
inhibitors) were previously mentioned[30-32]. However if  we 
Quantitative evaluation
Meta-analysis was performed for the following com-
parisons: antiplatelet drugs vs control, anticoagulant drugs 
vs control, and antithrombotic drugs (antiplatelet plus 
anticoagulant drugs) vs control.
While anticoagulation vs control data was derived from 
both WASH and HELAS studies[21,22], WASH study was 
the only that provided data for antiplatelet (acetylsalicylic 
acid) vs placebo[21]. For quantitative evaluation of  overall 
antithrombotic treatment in this population, we considered 
both oral anticoagulation and antiplatelet from WASH 
study as a single arm and efficacy was directly obtained 
from WASH study[21].
Primary outcome
Antithrombotic drugs did not reduce stroke risk against 
placebo or no treatment, with RR = 1.18 (95%CI: 
0.17-8.15) for antiplatelet drugs, RR = 0.30 (95%CI: 
0.03-2.65) for anticoagulants, and RR = 0.52 (95%CI: 
0.10-2.74) for overall antithrombotic drugs.
Secondary outcomes
Antithrombotic drugs showed an increased risk of  CHF 
worsening (RR = 1.61, 95%CI: 1.04-2.48), mainly due to 
the single antiplatelet drug studied, acetylsalicylic acid, 
which had RR = 1.78 (95%CI: 1.08-2.92), while oral 
anticoagulants were not different from controls (RR = 
1.03, 95%CI: 0.61-1.75).
Warfarin showed a significant increased risk of  major 
bleeding (RR = 9.00, 95%CI: 1.14-70.90) and acetylsalicylic 
acid showed a non-significant trend (RR = 3.26, 95%CI: 
0.13-79.04). The RR for overall major bleeding risk with 
antithrombotic drugs was 6.99 (95%CI: 0.89-54.64).
None of  the antithrombotic drugs or overall antith-
rombotic treatment showed reduction of  mortality and 
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Figure 2  Studies quality of reporting. WASH: Warfarin/Aspirin Study in Heart 
failure; HELAS: Heart failure Long-term Antithrombotic Study.
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consider warfarin as a “negative control”, the pooled rates 
of  HF worsening (after the WARCEF trial) were similar 
between acetylsalicylic acid and warfarin[7].
Along this century, antithrombotic treatment has gone 
forward in many therapeutic indications, but in patients 
with systolic HF and sinus rhythm the evidence to 
determine the prognostic importance of  antithrombotic 
treatment (individually or globally) remained stationary 
and unsatisfactory for those who have to deal with CHF 
patients with sinus rhythm.
Limitations
This systematic review with meta-analysis has limitations 
attributed to included studies and analysis method.
As for included studies, WASH study had an open-
label design; the control arm of  this study was a no-
antithrombotic treatment group (i.e., not a placebo 
controlled trial), and included 7% of  patients with AF 
that could not be excluded in the analyses. Furthermore 
the dosage of  acetylsalicylic acid used in this trial was 
considerably higher than recommended[33].
Both studies had different proportions of  HF etiologies. 
Although it can be important, particularly in ischemic 
HF cases where acetylsalicylic acid may play recognized 
prognostic role, here we aimed evaluate the thrombotic 
and embolic risk of  patients with clinically important left 
ventricle impairment.
Major bleeding definitions were not common along 
the included trials. Worsening HF was defined by the 
investigator in WASH and no definition was provided in 
HELAS.
Periods of  unrecognized paroxysmal AF could have 
biased of  results. However it would bias favouring the 
antithrombotic drugs, which did not occur.
In conclusions, current evidence does not support 
the routine use of  antithrombotic drugs (anticoagulant 
or antiplatelet drugs) for thromboprophylaxis in patients 
with systolic HF and sinus rhythm, as it carries a well 
known and documented bleeding risk without proven 
benefits compared to placebo or no antithrombotic 
treatment.
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Background
In patients with atrial fibrillation (AF), chronic heart failure (CHF) increases 
Outcomes and comparisons Risk ratio 95%CI Risk ratio 95%CI I 2 (%)
Stroke
   Antiplatelet vs  control 1.18 (0.17, 8.15) -
   OAC vs  control 0.30 (0.03, 2.65)   0
   ATT vs  control 0.52 (0.10, 2.74)   0
Mortality
   Antiplatelet vs  control 1.48 (0.88, 2.50) -
   OAC vs  control 0.87 (0.30, 2.50) 49
   ATT vs  control 1.36 (0.84, 2.19) 58
Myocardial infarction
   Antiplatelet vs  control 1.18 (0.43, 3.21) -
   OAC vs  control 0.75 (0.16, 3.53) 18
   ATT vs  control 1.27 (0.55, 2.94)   0
Worsening HF
   Antiplatelet vs  control 1.78 (1.08, 2.92) -
   OAC vs  control 1.03 (0.61, 1.75)   0
   ATT vs  control 1.61 (1.04, 2.48)   0
Major bleeding
   Antiplatelet vs  control   3.26 (0.13, 79.04) -
   OAC vs  control   9.00 (1.14, 70.90)   0
   ATT vs  control   6.99 (0.89, 54.64)   0
Mortality, stroke, myocardial infarction and HF
   Antiplatelet vs  control 1.34 (1.03, 1.74) -
   OAC vs  control 1.02 (0.77, 1.35)   0
   ATT vs  control 1.09 (0.72, 1.66) 25
0.05       0.2           1             5          20
Favours antithrombotic drugs     Favours control
Figure 3  Forest plot evaluating antithrombotic drugs vs control. Data for “Antiplatelet vs control” comparison derived from WASH study. ATT: Antithrombotic 
treatment; OAC: Oral anticoagulation; HF: Heart failure; WASH: Warfarin/Aspirin Study in Heart failure.
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thromboembolic risk and oral anticoagulation is essential to decrease the risk 
of thromboembolic complications. Evidence suggests a positive association 
between CHF, impaired hemostasis and thromboembolic events. Whether 
antithrombotic drugs have an prognosis impact in patients with CHF in sinus 
rhythm (i.e., without history of AF) is still very debated.
Research frontiers
Anticoagulation has been established as the gold standard treatment of 
stroke and embolism prevention in AF. The WARCEF trial did not show 
differences between warfarin and acetylsalicylic acid concerning major 
cardiovascular events in patients with CHF and sinus rhythm. Warfarin reduced 
the risk of ischemic stroke in this trial. However the efficacy of any of these 
drugs compared should be evaluated before drawing any conclusions and 
recommendations.
Innovations and breakthroughs
Based on the best available evidence (2 randomized controlled trials Warfarin/
Aspirin Study in Heart failure and Heart failure Long-term Antithrombotic Study), 
this systematic review emphasizes the lack of efficacy of any antithrombotic 
drugs (individually or pooled together) in patients with CHF and sinus rhythm. In 
addition should be considered that these drugs increase significantly the risk of 
major bleeding.
Applications 
Warfarin and acetylsalicylic acid should not be routinely used for throm-
boprophylaxis in patients with systolic HF and sinus rhythm, in the absence of 
concomitant comorbidities with clear indications for anticoagulation (e.g., AF) or 
acetylsalicylic acid (e.g., documented coronary artery disease).
Peer review
A systematic review and meta-analysis of two studies addressing antithrombotic 
drugs in patients with CHF and sinus rhythm. The manuscript is well written and 
adds new points to the discussion of anticoagulation.
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